An Indirect Comparison of Newer Minimally Invasive Treatments for Benign Prostatic Hyperplasia: A Network Meta-Analysis Model

Tanneru, Karthik; Jazayeri, Seyed Behzad; Alam, Muhammad Umar; Kumar, J.; Bazargani, Soroush; Kuntz, Gretchen; Ganapathi, Hariharan Palayapalayam; Bandyk, Mark; Marino, Robert; Koochekpour, Shahriar; Gautam, Shiva; Balaji, K.C.; Costa, Joseph

doi:10.1089/end.2020.0739

Cited by 37 publications

(42 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A meta-analysis of RCTs 24 of three recent innovations compared with TURP only found four papers. They made comparisons between TURP and Aquablation (one study), UroLift (two studies) and Rezum (one study).…”

Section: Prostatementioning

confidence: 99%

Which developments in urology have you missed amongst all the COVID‐19 papers?

Woodhouse

2022

Trends Urol & Men's Health

View full text Add to dashboard Cite

show abstract

Section: Prostatementioning

confidence: 99%

Which developments in urology have you missed amongst all the COVID‐19 papers?

Woodhouse

2022

Trends Urol & Men's Health

View full text Add to dashboard Cite

show abstract

“…The procedure is visualized using an integrated cystoscope with a standard 4 mm 30° lens. Saline irrigation is used to improve visualization and to cool down the urethral surface during the procedure [8][9][10][11][12].…”

Section: Rezum Proceduresmentioning

confidence: 99%

“…In [4][5][6][7][8][9][10][11][12] months post Rezum where one patient underwent PVP and 2 patients underwent redo Rezum [24]. From the available literature, the retreatment rate seems to be in the first 12 months post intervention with satisfactory durability.…”

Section: Retreatment Ratementioning

confidence: 99%

Rezum: a novel minimally invasive treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. A review article

Higazy

Osman

2021

Int Urol Nephrol

View full text Add to dashboard Cite

Lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) are one of the most common morbidities in elderly men, especially in aging societies. Minimally invasive surgical treatments (MISTs) for BPH have gained an increasing interest in the current time. Rezum system is a novel MIST that uses water vapour-based convective thermal therapy to ablate prostatic tissue. According to our evaluation of the existing literature, Rezum offers a meaningful relief of LUTS with a high safety profile without compromising the sexual activity especially to those who are unfit for surgery or to those who do not desire to continue on lifelong pharmacotherapy.

show abstract

“…On the other hand, a meta-analysis aiming to compare the newer minimally invasive treatments for BPH, evaluated four randomized-controlled trials reporting the outcomes after treatment. 27 The authors found that with respect to urinary domain outcomes such as IPSS, peak flow rate, and PVR, ablative measures such as TURP and Aquablation showed greater improvement when compared to non-resective procedures such as Rezum and PUL. 27 However, consistent with previous studies, patients who underwent PUL maintained a higher sexual function when compared to those undergoing TURP.…”

Section: Outcomes Following the Lift Trialmentioning

confidence: 98%

“… 27 The authors found that with respect to urinary domain outcomes such as IPSS, peak flow rate, and PVR, ablative measures such as TURP and Aquablation showed greater improvement when compared to non-resective procedures such as Rezum and PUL. 27 However, consistent with previous studies, patients who underwent PUL maintained a higher sexual function when compared to those undergoing TURP. Conversely to the work of Tutrone et al, the authors of this study did not experience a significant difference in urinary and sexual outcomes in patients undergoing PUL versus Rezum at two years of follow-up.…”

Section: Outcomes Following the Lift Trialmentioning

confidence: 98%

An Update on the Outcomes of Patients Treated with Urolift for Benign Prostatic Hyperplasia

Loloi

Feiertag

Gautam

et al. 2021

RRU

View full text Add to dashboard Cite

Benign prostatic hyperplasia (BPH) is a ubiquitous urologic disease affecting aging men. Patients often experience bothersome lower urinary tract symptoms (LUTS) that warrant urologic evaluation and management. Routinely, patients are initially treated with medical therapies with the goal of both relaxing the bladder neck and shrinking the prostate in order to relieve obstruction secondary to prostatic enlargement. Transurethral resection of the prostate (TURP) serves as a first-line surgical intervention in those who fail medical therapy. Recently, novel minimally invasive surgical techniques for BPH management have emerged. Of these, prostatic urethral lift (PUL or Urolift) has gained attention given its presumed effectiveness and minimal risk of sexual side effects when compared to the standard TURP. The purpose of this review is to describe past and current trends in the implementation of PUL for BPH and to highlight important outcomes.

show abstract

An Indirect Comparison of Newer Minimally Invasive Treatments for Benign Prostatic Hyperplasia: A Network Meta-Analysis Model

Cited by 37 publications

References 18 publications

Which developments in urology have you missed amongst all the COVID‐19 papers?

Which developments in urology have you missed amongst all the COVID‐19 papers?

Rezum: a novel minimally invasive treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. A review article

An Update on the Outcomes of Patients Treated with Urolift for Benign Prostatic Hyperplasia

Contact Info

Product

Resources

About